BioAtla, Inc , a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
infoBioAtla is a micro cap stock with a total market cap of 122.51M.
infoThey trade on the NASDAQ and had their IPO 2 years and 8 months ago.
infoBioAtla currently employs 66 people.
infoAs of Wednesday, Aug 23 2023, BioAtla’s share price is $2.57.
News Relating to BioAtla
GlobeNewsWire
BioAtla to Participate in Upcoming Investor Conferences in August
Thursday Aug 03 2023 at 16:01
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in two upcoming investor conferences, to be held in August 2023.
Seeking Alpha
BioAtla, Inc. (BCAB) Q2 2023 Earnings Call Transcript
Tuesday Aug 01 2023 at 23:18
BioAtla, Inc. (NASDAQ:BCAB ) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Bruce Mackle – IR, LifeSci Advisors, LLC Jay Short – Chairman & Chief Medical Officer Richard Waldron – Chief Financial Officer Eric Sievers – Chief Medical Officer Sheri Lydick – Chief Commercial Officer Conference Call Participants Brian Cheng – JPMorgan Kaveri Pohlman – BTIG Arthur He – H.C. Wainwright Tony Butler – E.F.
GlobeNewsWire
BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023
Tuesday Jul 25 2023 at 08:00
SAN DIEGO, July 25, 2023 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, August 1, 2023 at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2023 and provide business highlights.
Seeking Alpha
BioAtla, Inc. (BCAB) Q1 2023 Earnings Call Transcript
Thursday May 11 2023 at 22:51
BioAtla, Inc. (NASDAQ:BCAB ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Bruce Mackle – IR, LifeSci Advisors, LLC Jay Short – Chairman and CEO Richard Waldron – CFO Philippe Martin – Chief CDO Conference Call Participants Brian Cheng – JPMorgan Kaveri Pohlman – BTIG Reni Benjamin – JMP Securities Arthur He – H.C. Wainwright Operator Greetings.
GlobeNewsWire
BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023
Thursday May 04 2023 at 08:00
SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, May 11, 2023 at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2023 and provide business highlights.
Seeking Alpha
BioAtla, Inc. (BCAB) Q4 2022 Earnings Call Transcript
Thursday Mar 23 2023 at 22:33
BioAtla, Inc. (NASDAQ:BCAB ) Q4 2022 Earnings Call Transcript March 23, 2023 4:30 PM ET Company Participants Bruce Mackle – Investor Relations, LifeSci Advisors, LLC Jay Short – Chairman, Chief Executive Officer and Cofounder Richard Waldron – Chief Financial Officer Philippe Martin – Chief Clinical Development and Operations Conference Call Participants Brian Cheng – JPMorgan Kelly Shi – Jefferies Tony Buter – EF Hutton Arthur He – H.C. Wainwright Reni Benjamin – JMP Securities Operator Greetings.
Barrons
7 Cheap But Risky Biotech Stocks
Wednesday Jan 18 2023 at 13:58
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.
Zacks Investment Research
Can BioAtla, Inc. (BCAB) Climb 260% to Reach the Level Wall Street Analysts Expect?
Tuesday Nov 15 2022 at 11:18
The mean of analysts’ price targets for BioAtla, Inc. (BCAB) points to a 259.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Seeking Alpha
BioAtla, Inc. (BCAB) Q3 2022 Earnings Call Transcript
Sunday Nov 06 2022 at 11:47
BioAtla, Inc. (NASDAQ:BCAB ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Bruce Mackle – Investor Relations Jay Short – Chairman, Chief Executive Officer and Co-Founder Scott Smith – President Philippe Martin – Chief, Clinical Development and Operations Sheri Lydick – Senior Vice President, Commercial Strategy Richard Waldron – Chief Financial Officer Conference Call Participants Brian Cheng – JPMorgan Kelly Shi – Jefferies Tony Butler – ROTH Capital Arthur He – H.C. Wainwright Reni Benjamin – JMP Securities Operator Good day and welcome to the BioAtla Third Quarter 2022 Earnings Conference Call – pardon me, BioAtla.
Zacks Investment Research
BioAtla, Inc. (BCAB) Reports Q3 Loss, Lags Revenue Estimates
Friday Nov 04 2022 at 12:48
BioAtla, Inc. (BCAB) delivered earnings and revenue surprises of 10.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewsWire
BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022
Thursday Oct 27 2022 at 08:00
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, November 3, 2022 at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2022 and provide business highlights.
Seeking Alpha
BioAtla: Back From The Dead
Friday Sep 23 2022 at 16:12
Shares of conditionally active biologics concern BioAtla, Inc. are beginning to rebound from a 97% plunge as encouraging data from two candidates has sparked the turnaround. BioAtla leverages its expertise of the tumor microenvironment to develop highly selective and reversible biologics, with applications across the entire antibody-based biologic spectrum.
Seeking Alpha
BioAtla: Promising Signal In NSCLC, But Concerns Remain
Tuesday Aug 23 2022 at 09:46
BioAlta shares have lost nearly three-quarters of their value over the past 3 years. Management has not done a good job of keeping lines of communication open and has a history of postponing clinical data timelines.
Seeking Alpha
BioAtla, Inc. (BCAB) CEO Jay Short on Q2 2022 Results – Earnings Call Transcript
Saturday Aug 13 2022 at 15:18
BioAtla, Inc. (NASDAQ:BCAB ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Bruce Mackle – LifeSci Advisors Jay Short – Chairman, CEO and Co-Founder Scott Smith – President Philippe Martin – Chief of Clinical Development and Operations Sheri Lydick – SVP, Commercial Strategy Richard Waldron – CFO Conference Call Participants Kelly Shi – Jefferies Arthur He – H.C. Wainwright Tony Butler – ROTH Capital Operator Hello and welcome to the BioAtla Second Quarter 2022 Earnings Call.
Zacks Investment Research
BioAtla, Inc. (BCAB) Reports Q2 Loss, Lags Revenue Estimates
Tuesday Aug 09 2022 at 21:04
BioAtla, Inc. (BCAB) delivered earnings and revenue surprises of -10% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewsWire
BioAtla to Announce Second Quarter 2022 Financial Results and Provide Business Highlights on August 9, 2022
Tuesday Aug 02 2022 at 08:00
SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, August 9, 2022 at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2022 and provide business highlights.
GlobeNewsWire
BioAtla to Participate in 2022 Jefferies Global Healthcare Conference
Wednesday Jun 01 2022 at 16:05
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that Jay M. Short, Ph.D., Chairman, Chief Executive Officer and co-founder, and Scott Smith, President, will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference, to be held in-person in New York, NY June 8-10, 2022.
Seeking Alpha
BioAtla, Inc. (BCAB) CEO Jay Short on Q1 2022 Results – Earnings Call Transcript
Saturday May 07 2022 at 15:06
BioAtla, Inc. (NASDAQ:BCAB ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Bruce Mackle – LifeSci Advisors Jay Short – Chairman, CEO and Co-Founder Scott Smith – President Philippe Martin – Chief of Clinical Development and Operations Sheri Lydick – Senior Vice President, Commercial Strategy Richard Waldron – Chief Financial Officer Conference Call Participants Anupam Rama – JPMorgan Tiago Fauth – Credit Suisse Kelly Shi – Jefferies Kaveri Pohlman – BTIG Tony Butler – ROTH Capital Arthur He – H.C. Wainwright Operator Good day, and thank you for standing by.
GlobeNewsWire
BioAtla to Announce First Quarter 2022 Financial Results and Provide Business Highlights on May 4, 2022
Friday Apr 08 2022 at 08:00
SAN DIEGO, April 08, 2022 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody and other protein therapeutics, today announced that it plans to host a conference call and webcast on Wednesday, May 4, 2022 at 4:30 p.m. Eastern Time to discuss its financial results for the quarter ended March 31, 2022, and provide an interim topline data update from the mecbotamab vedotin (BA3011) Phase 2 study in sarcoma as well as an operational update on our ongoing clinical programs, including BA3011, ozuriftamab vedotin (BA3021) and CAB-CTLA-4 (BA3071).
PRNewsWire
BioAtla Announces Private Placement of 2.7 Million Shares
Wednesday Sep 29 2021 at 08:03
SAN DIEGO, Sept. 29, 2021 /PRNewswire/ — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into stock purchase agreements with a group of institutional investors in connection with a private placement of its common stock.
PRNewsWire
BioAtla Announces Second Quarter 2021 Financial Results And Provides Clinical Update
Friday Aug 13 2021 at 17:54
SAN DIEGO, Aug. 13, 2021 /PRNewswire/ — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced financial results for the second quarter of 2021 and provided an update on its business. “BioAtla is advancing potentially registration-enabling Phase 2 clinical trials for our two lead CAB product candidates.
PRNewsWire
BioAtla Announces First Quarter 2021 Financial Results And Provides Business Update
Wednesday May 12 2021 at 18:26
SAN DIEGO, May 12, 2021 /PRNewswire/ — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced financial results for the first quarter of 2021 and provided an update on its business. “BioAtla is rapidly advancing potentially registration-enabling Phase 2 clinical trials for our two lead CAB product candidates.
Seeking Alpha
BioAtla: Intriguing Science, New IPO, A Name To Watch
Sunday Feb 07 2021 at 07:29
BioAtla is developing selectively-targeting antibodies based on very interesting science. However, it is a new IPO, and current prices and cash reserves are not conducive to investment.
Benzinga
Notable Insider Buys In The Week Of Christmas: Foot Locker, GameStop, NetApp And More
Saturday Dec 26 2020 at 13:53
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when there is uncertainty in the markets, as there has been due to the pandemic resurgence and political issues.
PRNewsWire
BioAtla Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Friday Dec 18 2020 at 16:00
SAN DIEGO, Dec. 18, 2020 /PRNewswire/ — BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer, today announced the closing of its initial…
PRNewsWire
BioAtla Announces Pricing of Initial Public Offering
Tuesday Dec 15 2020 at 19:59
SAN DIEGO, Dec. 15, 2020 /PRNewswire/ — BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer, today announced the pricing of its initial…
BioAtla Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
BioAtla’s Altman Z-score is -2.72 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
BioAtla Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, there has been no insider trading in BioAtla.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
BioAtla’s Income Quality of 1.3 is greater than its Industry Group of 0.69 (88.4% greater)
BioAtla’s Income Quality of 1.3 is greater than its Major Industry Group of 0.71 (83.1% greater)
BioAtla’s Income Quality of 1.3 is greater than its Sector of 0.75 (73.3% greater)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
BioAtla’s Current Ratio of 5.21 is in line with its Industry Group of 4.76 (9.5% greater)
BioAtla’s Current Ratio of 5.21 is greater than its Major Industry Group of 4.32 (20.6% greater)
BioAtla’s Current Ratio of 5.21 is greater than its Sector of 2.6 (100.4% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-1.55 & -1.27)
Cannot compare a negative PE Ratio (-1.55 & -1.1)
Cannot compare a negative PE Ratio (-1.55 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
BioAtla’s PB Ratio of 0.98 is lower than its Industry Group of 1.34 (-26.9% lower)
BioAtla’s PB Ratio of 0.98 is lower than its Major Industry Group of 1.4 (-30.0% lower)
BioAtla’s PB Ratio of 0.98 is lower than its Sector of 1.62 (-39.5% lower)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
BioAtla’s ROE of -0.64 is lower than its Industry Group of -0.44 (-45.5% lower)
BioAtla’s ROE of -0.64 is lower than its Major Industry Group of -0.38 (-68.4% lower)
BioAtla’s ROE of -0.64 is lower than its Sector of -0.03 (-2033.3% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
BioAtla’s ROCE of -0.83 is lower than its Industry Group of -0.42 (-97.6% lower)
BioAtla’s ROCE of -0.83 is lower than its Major Industry Group of -0.37 (-124.3% lower)
BioAtla’s ROCE of -0.83 is lower than its Sector of -0.04 (-1975.0% lower)
Derived from SEC.GOV filing dataopen_in_new